Ellipticine compounds for treating obesity
US8513274B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 15, 2010 |
| Grant date | Aug 20, 2013 |
| Priority date | — |
| Expiry date | Dec 20, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method of reducing body weight in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I:In Formula I, R1 is H, C1-6 alkyl, or C1-6 alkyl-aryl. Each of R2 and R4 of Formula I are independently H, halogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkoxy, —OR2a, —SR2a, —C(O)R2a, —C(O)OR2a, —C(O)NR2aR2b, —NR2aR2b, C1-6 alkyl-NR2aR2b, —N(R2a)C(O)R2b, —N(R2a)C(O)OR2b, —N(R2a)C(O)NR2aR2b, —OP(O)(OR2a)2, —S(O)2OR2a, —S(O)2NR2aR2b, —CN, —NO2, cycloalkyl, heterocycloalkyl, aryl or heteroaryl. Each of R2a and R2b of Formula I are independently H, C1-6 alkyl, C1-10 heteroalkyl or C1-6 alkyl-aryl. R3 of Formula I is absent, C1-6 alkyl or N-oxide. The compounds include the salts, hydrates and isomers thereof. The present invention also provides methods for the treatment of obesity and disorders related to obesity and higher than recommended percentage body fat, such as type II diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.